- ￥4500
- Sino Biological
- 40592-V08H121
- 2025年08月12日
企业认证
相关产品推荐更多 >
SARS-CoV-2 (2019-nCoV) Spike S1(D614G),ECD-Fc重组蛋白
￥4500
Coronavirus spike重组蛋白|Recombinant SARS-CoV-2 Spike RBD (T478K) Protein (His Tag)
￥4500
Influenza A H1N1 (A/Solomon Islands/3/2006) Hemagglutinin Protein (HA1 Subunit) (His Tag)
￥4520
HIV gp120重组蛋白|Recombinant HIV gp120 Protein (His & AVI Tag), Biotinylated
￥3220Influenza A H3N2 (A/Missouri/09/2014) Hemagglutinin / HA1 Protein (His Tag)
￥4520
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 规格：
100 µg
重组新冠病毒 B.1.1.529 (Omicron) Spike RBD 蛋白 (His标签)（产品说明）
蛋白名称：SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD Protein (His Tag)
蛋白构建：A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa.
表达宿主：HEK293 Cells
蛋白纯度：> 95 % as determined by SDS-PAGE. > 95 % as determined by SEC-HPLC.
蛋白活性：Immobilized human ACE2 protein (mFc tag)(Cat: 10108-H05H) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD Protein (His Tag)(Cat: 40592-V08H121), the EC50 is 3-10 ng/mL.
蛋白内毒素：< 1.0 EU per μg protein as determined by the LAL method.
预测N端：Arg 319
蛋白分子量：The recombinant SARS-CoV-2 Spike RBD consists of 234 amino acids and predicts a molecular mass of 26.83 kDa.
蛋白NP号：YP_009724390.1
蛋白氨基酸序列：Arg319-Phe541
蛋白标签：C-His
蛋白保存条件：Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
蛋白名称：SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD Protein (His Tag)
蛋白构建：A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa.
表达宿主：HEK293 Cells
蛋白纯度：> 95 % as determined by SDS-PAGE. > 95 % as determined by SEC-HPLC.
蛋白活性：Immobilized human ACE2 protein (mFc tag)(Cat: 10108-H05H) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 B.1.1.529 (Omicron) Spike RBD Protein (His Tag)(Cat: 40592-V08H121), the EC50 is 3-10 ng/mL.
蛋白内毒素：< 1.0 EU per μg protein as determined by the LAL method.
预测N端：Arg 319
蛋白分子量：The recombinant SARS-CoV-2 Spike RBD consists of 234 amino acids and predicts a molecular mass of 26.83 kDa.
蛋白NP号：YP_009724390.1
蛋白氨基酸序列：Arg319-Phe541
蛋白标签：C-His
蛋白保存条件：Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验该产品被引用文献
1, Li Y, et al. Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants.iScience, PubMed ID: 35607524
2, Wang S, et al. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.Cell reports, PubMed ID: 35594869
3, Chen C, et al. Potent and Broad Neutralization of SARS-CoV-2 Variants of Concern (VOCs) including Omicron Sub-lineages BA.1 and BA.2 by Biparatopic Human VH Domains.iScience, PubMed ID: 35875685
4, Emmenegger M, et al. Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants.iScience, PubMed ID: 35875683
5, Hawman DW, et al. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.EBioMedicine, PubMed ID: 35932641
6, Forte E, et al. Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS.Journal of proteome research, PubMed ID: 36343328
7, Saville JW, et al. Structural analysis of receptor engagement and antigenic drift within the BA.2 spike protein.Cell reports, PubMed ID: 36640338
8, Song Z, et al. Analysis of Antibodies Induced after SARS-CoV-2 Vaccination Using Antigen Coded Bead Array Luminex Technology.Vaccines, PubMed ID: 36851319
9, Emmenegger M, et al. Protocol to determine antibody affinity and concentration in complex solutions using microfluidic antibody affinity profiling.STAR protocols, PubMed ID: 36853663
10, Carlson EC, et al. The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline.International journal of molecular sciences, PubMed ID: 36982671
11, Verstraete MM, et al. Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2.mAbs, PubMed ID: 37229608
12, Wang Y, et al. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants.Nature communications, PubMed ID: 38287016
13, Yang M, et al. Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity.Signal transduction and targeted therapy, PubMed ID: 38355661
14, Poulakou G, et al. Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.Frontiers in immunology, PubMed ID: 38694503
15, Park S, et al. An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation.Nature communications, PubMed ID: 38643233
16, Chiu CT, et al. An Immunoreceptor-Targeting Strategy with Minimalistic C3b Peptide Fusion Enhances SARS-CoV-2 RBD mRNA Vaccine Immunogenicity.International journal of nanomedicine, PubMed ID: 39050877
17, García-Silva I, et al. Synthesis and Characterization of Thiolated Nanoparticles Based on Poly (Acrylic Acid) and Algal Cell Wall Biopolymers for the Delivery of the Receptor Binding Domain from SARS-CoV-2.Pharmaceutics, PubMed ID: 39065588
2, Wang S, et al. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.Cell reports, PubMed ID: 35594869
3, Chen C, et al. Potent and Broad Neutralization of SARS-CoV-2 Variants of Concern (VOCs) including Omicron Sub-lineages BA.1 and BA.2 by Biparatopic Human VH Domains.iScience, PubMed ID: 35875685
4, Emmenegger M, et al. Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants.iScience, PubMed ID: 35875683
5, Hawman DW, et al. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.EBioMedicine, PubMed ID: 35932641
6, Forte E, et al. Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS.Journal of proteome research, PubMed ID: 36343328
7, Saville JW, et al. Structural analysis of receptor engagement and antigenic drift within the BA.2 spike protein.Cell reports, PubMed ID: 36640338
8, Song Z, et al. Analysis of Antibodies Induced after SARS-CoV-2 Vaccination Using Antigen Coded Bead Array Luminex Technology.Vaccines, PubMed ID: 36851319
9, Emmenegger M, et al. Protocol to determine antibody affinity and concentration in complex solutions using microfluidic antibody affinity profiling.STAR protocols, PubMed ID: 36853663
10, Carlson EC, et al. The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline.International journal of molecular sciences, PubMed ID: 36982671
11, Verstraete MM, et al. Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2.mAbs, PubMed ID: 37229608
12, Wang Y, et al. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants.Nature communications, PubMed ID: 38287016
13, Yang M, et al. Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity.Signal transduction and targeted therapy, PubMed ID: 38355661
14, Poulakou G, et al. Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.Frontiers in immunology, PubMed ID: 38694503
15, Park S, et al. An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation.Nature communications, PubMed ID: 38643233
16, Chiu CT, et al. An Immunoreceptor-Targeting Strategy with Minimalistic C3b Peptide Fusion Enhances SARS-CoV-2 RBD mRNA Vaccine Immunogenicity.International journal of nanomedicine, PubMed ID: 39050877
17, García-Silva I, et al. Synthesis and Characterization of Thiolated Nanoparticles Based on Poly (Acrylic Acid) and Algal Cell Wall Biopolymers for the Delivery of the Receptor Binding Domain from SARS-CoV-2.Pharmaceutics, PubMed ID: 39065588
相关实验
日前，北京大学生命科学学院魏文胜课题组在 Cell 杂志上在线发表题为“Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants”的研究论文。 魏文胜团队首先建立了体外高效制备高纯度环状 RNA 的技术平台，针对新型冠状病毒及其变异株，设计了编码新冠病毒刺突蛋白（Spike）受体结构域（RBD）的环状 RNA 疫苗。 该项研究中制备的针对新冠病毒德尔塔变异株的环状 RNA 疫苗（circRNARBD
全球首次！分离的新冠病毒中和抗体，还可同时抗 SARS 病毒
抗原表位，为预防和治疗新型冠状病毒肺炎 COVID- 19 提供了可能。图片来源：bioRxiv通常，冠状病毒中和抗体主要靶向介导进入宿主细胞的病毒表面三聚体刺突糖蛋白（Spike Glycoproteins，S 蛋白）。S 蛋白具有介导细胞附着的两个功能亚基：负责受体识别的 S1 亚基（存在四个核心结构域 S1 A/B/C/D）以及促使病毒与细胞膜融合的 S2 亚基。强大的中和抗体通常会靶向 S1 中的受体相互作用位点，从而使受体相互作用失效。之前的研究表明，SARS-CoV- 2 和 SARS-CoV
中科院高福院士课题组 2020 年发表了哪些重要的研究成果？
和 H4 阻断病毒的尖峰糖蛋白受体结合域（RBD）与细胞受体血管紧张素转化酶 2（ACE2）之间的结合。竞争分析表明这两种抗体在 RBD 上具有不同的表位，使其成为潜在有希望的靶向病毒的单克隆抗体对，从而避免了未来临床应用中的免疫逃逸。此外，在小鼠模型中进行的一项治疗研究证实，这些抗体可以降低感染肺部的病毒滴度。RBD-B38 复杂结构表明，表位上的大多数残基与 RBD-ACE2 结合界面重叠，从而说明了阻断作用和中和能力。研究结果突出了基于抗体的疗法的前景，并为合理疫苗设计提供了结构基础。 图源
技术资料暂无技术资料 索取技术资料
文献支持
重组新冠病毒 B.1.1.529 (Omicron) Spike RBD 蛋白 (His标签)
￥4500
